Fusen Pharmaceutical Company Limited (1652.HK)
HKD 0.26
(4.0%)
HKD 0.26
(4.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 781.51 Million CNY | 5.99% |
| 2022 | 737.37 Million CNY | 26.61% |
| 2021 | 582.39 Million CNY | -0.12% |
| 2020 | 583.09 Million CNY | 17.87% |
| 2019 | 494.68 Million CNY | -9.59% |
| 2018 | 547.16 Million CNY | -28.8% |
| 2017 | 768.44 Million CNY | -24.99% |
| 2016 | 1.02 Billion CNY | -12.23% |
| 2015 | 1.16 Billion CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 818.21 Million CNY | 0.0% |
| 2024 Q1 | 818.21 Million CNY | 4.7% |
| 2023 Q1 | 691.44 Million CNY | -6.23% |
| 2023 FY | 781.51 Million CNY | 5.99% |
| 2023 Q4 | 781.51 Million CNY | 0.0% |
| 2023 Q3 | 781.51 Million CNY | 13.03% |
| 2023 Q2 | 691.44 Million CNY | 0.0% |
| 2022 Q3 | 737.37 Million CNY | 27.39% |
| 2022 FY | 737.37 Million CNY | 26.61% |
| 2022 Q2 | 578.83 Million CNY | 0.0% |
| 2022 Q1 | 578.83 Million CNY | -0.61% |
| 2022 Q4 | 737.37 Million CNY | 0.0% |
| 2021 Q1 | 588.89 Million CNY | 0.99% |
| 2021 Q3 | 582.39 Million CNY | -1.1% |
| 2021 Q4 | 582.39 Million CNY | 0.0% |
| 2021 FY | 582.39 Million CNY | -0.12% |
| 2021 Q2 | 588.89 Million CNY | 0.0% |
| 2020 Q1 | 548.82 Million CNY | 10.94% |
| 2020 FY | 583.09 Million CNY | 17.87% |
| 2020 Q4 | 583.09 Million CNY | 0.0% |
| 2020 Q3 | 583.09 Million CNY | 6.24% |
| 2020 Q2 | 548.82 Million CNY | 0.0% |
| 2019 Q3 | 494.68 Million CNY | 7.63% |
| 2019 Q1 | 445.3 Million CNY | -18.62% |
| 2019 Q2 | 459.6 Million CNY | 3.21% |
| 2019 FY | 494.68 Million CNY | -9.59% |
| 2019 Q4 | 494.68 Million CNY | 0.0% |
| 2018 Q2 | 638.44 Million CNY | 0.0% |
| 2018 Q4 | 547.16 Million CNY | 0.0% |
| 2018 Q3 | 547.16 Million CNY | -14.3% |
| 2018 FY | 547.16 Million CNY | -28.8% |
| 2018 Q1 | 638.44 Million CNY | -16.92% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 Q4 | 768.44 Million CNY | 0.0% |
| 2017 FY | 768.44 Million CNY | -24.99% |
| 2016 Q4 | 1.02 Billion CNY | 0.0% |
| 2016 FY | 1.02 Billion CNY | -12.23% |
| 2015 FY | 1.16 Billion CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | -449.275% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 89.213% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | -358.619% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | -10.127% |
| Qianhai Health Holdings Limited | 94 Million HKD | -731.377% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | 15.972% |
| Essex Bio-Technology Limited | 903.78 Million HKD | 13.528% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | -17.453% |
| PuraPharm Corporation Limited | 689.65 Million HKD | -13.321% |
| SSY Group Limited | 4.49 Billion HKD | 82.609% |
| JBM (Healthcare) Limited | 366.75 Million HKD | -113.091% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | 28.333% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 99.536% |